Wei-Jie Guan1, Yong-Hua Gao1, Gang Xu1, Hui-Min Li1, Jing-Jing Yuan1, Jin-Ping Zheng1, Rong-Chang Chen1, Nan-Shan Zhong1. 1. 1 State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 2 Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China ; 3 Guangzhou First People's Hospital, Guangzhou 510120, China.
Abstract
BACKGROUND: Bronchial dilation testing is an important tool to assess airway reversibility in adults with bronchiectasis. This study aims to investigate the association of bronchodilator response (BDR) and clinical parameters in bronchiectasis, and the utility of BDR to indicate lung function decline and risks of bronchiectasis exacerbations (BEs). METHODS: We recruited 129 patients with clinically stable bronchiectasis. Baseline measurements included assessment of sputum inflammation and matrix metalloproteinase-8 and -9, sputum bacterial culture, spirometry, bronchial dilation test (for baseline FEV1 less than 80% predicted only) and chest high-resolution computed tomography (HRCT). Bronchiectasis patients were followed-up for 1 year to determine the incidence of BEs and lung function trajectories. Significant BDR was defined as FEV1 improvement from pre-dose value by at least 200 mL and 12%. Clinical trial registry No.: NCT01761214; URL: www.clinicaltrials.gov. RESULTS: BDR was negatively correlated with baseline FEV1 percentage predicted, but not blood or sputum eosinophil count. Significant BDR was not associated with greater proportion of never-smokers, poorer past history, greater HRCT scores, poorer diffusing capacity or increased sputum matrix metalloproteinases (all P>0.05). There was a trend towards higher bronchiectasis severity index (BSI) and greater proportion of patients with Pseudomonas aeruginosa isolation or infection. Significant BDR at baseline was linked to poorer spirometry, but not more rapid lung function decline, throughout follow-up. Patients with significant BDR demonstrated non-significantly lower risks of experiencing the first BEs than those without (P=0.09 for log-rank test). CONCLUSIONS: Significant BDR is associated with poorer lung function compared with non-significant BDR. Whether BDR predicts future risks of BEs needs to be tested in a larger cohort.
BACKGROUND: Bronchial dilation testing is an important tool to assess airway reversibility in adults with bronchiectasis. This study aims to investigate the association of bronchodilator response (BDR) and clinical parameters in bronchiectasis, and the utility of BDR to indicate lung function decline and risks of bronchiectasis exacerbations (BEs). METHODS: We recruited 129 patients with clinically stable bronchiectasis. Baseline measurements included assessment of sputum inflammation and matrix metalloproteinase-8 and -9, sputum bacterial culture, spirometry, bronchial dilation test (for baseline FEV1 less than 80% predicted only) and chest high-resolution computed tomography (HRCT). Bronchiectasispatients were followed-up for 1 year to determine the incidence of BEs and lung function trajectories. Significant BDR was defined as FEV1 improvement from pre-dose value by at least 200 mL and 12%. Clinical trial registry No.: NCT01761214; URL: www.clinicaltrials.gov. RESULTS: BDR was negatively correlated with baseline FEV1 percentage predicted, but not blood or sputum eosinophil count. Significant BDR was not associated with greater proportion of never-smokers, poorer past history, greater HRCT scores, poorer diffusing capacity or increased sputum matrix metalloproteinases (all P>0.05). There was a trend towards higher bronchiectasis severity index (BSI) and greater proportion of patients with Pseudomonas aeruginosa isolation or infection. Significant BDR at baseline was linked to poorer spirometry, but not more rapid lung function decline, throughout follow-up. Patients with significant BDR demonstrated non-significantly lower risks of experiencing the first BEs than those without (P=0.09 for log-rank test). CONCLUSIONS: Significant BDR is associated with poorer lung function compared with non-significant BDR. Whether BDR predicts future risks of BEs needs to be tested in a larger cohort.
Authors: M C Pasteur; S M Helliwell; S J Houghton; S C Webb; J E Foweraker; R A Coulden; C D Flower; D Bilton; M T Keogan Journal: Am J Respir Crit Care Med Date: 2000-10 Impact factor: 21.405
Authors: K W Tsang; K C Tan; P L Ho; G C Ooi; J C Ho; J Mak; G L Tipoe; C Ko; C Yan; W K Lam; M Chan-Yeung Journal: Thorax Date: 2005-03 Impact factor: 9.139
Authors: Changhwan Kim; Joon Beom Seo; Sang Min Lee; Jae Seung Lee; Jin Won Huh; Jin Hwa Lee; Seung Won Ra; Ji-Hyun Lee; Eun-Kyung Kim; Tae-Hyung Kim; Woo Jin Kim; Sang-Min Lee; Sang Yeub Lee; Seong Yong Lim; Tae Rim Shin; Ho Il Yoon; Seung Soo Sheen; Yeon-Mok Oh; Yong Bum Park; Sang-Do Lee Journal: Respiration Date: 2012-12-11 Impact factor: 3.580
Authors: K W Tsang; P L Ho; W K Lam; M S Ip; K N Chan; C S Ho; C C Ooi; K Y Yuen Journal: Am J Respir Crit Care Med Date: 1998-09 Impact factor: 21.405
Authors: L Watson; J M Vonk; C G Löfdahl; N B Pride; R A Pauwels; L A Laitinen; J P Schouten; D S Postma Journal: Respir Med Date: 2005-09-30 Impact factor: 3.415
Authors: Rodrigo Athanazio; Mônica Corso Pereira; Georgina Gramblicka; Fernando Cavalcanti-Lundgren; Mara Fernandes de Figueiredo; Francisco Arancibia; Samia Rached; David de la Rosa; Luis Máiz-Carro; Rosa Girón; Casilda Olveira; Concepción Prados; Miguel Angel Martinez-Garcia Journal: BMC Pulm Med Date: 2017-04-26 Impact factor: 3.317